Nova EYE Medical Ltd (AU:EYE) — Market Cap & Net Worth
Market Cap & Net Worth: Nova EYE Medical Ltd (EYE)
Nova EYE Medical Ltd (AU:EYE) has a market capitalization of $26.20 Million (AU$37.03 Million) as of September 23, 2026. Listed on the AU stock exchange, this Australia-based company holds position #24309 globally and #969 in its home market, demonstrating a -3.70% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Nova EYE Medical Ltd's stock price AU$0.13 by its total outstanding shares 284875284 (284.88 Million). Also see EYE asset base for a full breakdown of the balance sheet.
Nova EYE Medical Ltd Market Cap History: 2015 to 2026
Nova EYE Medical Ltd's market capitalization history from 2015 to 2026. Data shows growth from $37.09 Million to $26.20 Million (0.53% CAGR). Also see cash flow conversion of Nova EYE Medical Ltd for how efficiently the company converts equity into cash flow.
Nova EYE Medical Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Nova EYE Medical Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Nova EYE Medical Ltd stock quote for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.75x
Nova EYE Medical Ltd's market cap is 0.75 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $47.73 Million | $71.81 Million | -$894.00K | 0.66x | N/A |
| 2018 | $34.13 Million | $79.43 Million | -$5.07 Million | 0.43x | N/A |
| 2019 | $38.34 Million | $16.14 Million | -$6.66 Million | 2.38x | N/A |
| 2020 | $71.56 Million | $12.77 Million | -$6.99 Million | 5.60x | N/A |
| 2021 | $68.53 Million | $13.39 Million | -$4.36 Million | 5.12x | N/A |
| 2022 | $56.44 Million | $13.38 Million | -$7.50 Million | 4.22x | N/A |
| 2023 | $48.38 Million | $17.02 Million | -$15.29 Million | 2.84x | N/A |
| 2024 | $32.25 Million | $23.32 Million | -$8.79 Million | 1.38x | N/A |
| 2025 | $26.71 Million | $29.27 Million | -$9.06 Million | 0.91x | N/A |
| 2026 | $26.20 Million | $34.87 Million | -$4.33 Million | 0.75x | N/A |
Competitor Companies of EYE by Market Capitalization
Companies near Nova EYE Medical Ltd in the global market cap rankings as of September 23, 2026. Review EYE tangible net worth ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Nova EYE Medical Ltd by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #122 globally with a market cap of $180.30 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #228 globally with a market cap of $109.30 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #237 globally with a market cap of $105.52 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #240 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #122 | Abbott Laboratories | NYSE:ABT | $180.30 Billion | $103.69 |
| #228 | Medtronic PLC | NYSE:MDT | $109.30 Billion | $90.77 |
| #237 | Stryker Corporation | NYSE:SYK | $105.52 Billion | $275.09 |
| #240 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
Nova EYE Medical Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Nova EYE Medical Ltd's market cap moved from $37.09 Million to $ 26.20 Million, with a yearly change of 0.53%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$26.20 Million | -1.89% |
| 2025 | AU$26.71 Million | -17.19% |
| 2024 | AU$32.25 Million | -33.33% |
| 2023 | AU$48.38 Million | -14.29% |
| 2022 | AU$56.44 Million | -17.65% |
| 2021 | AU$68.53 Million | -4.23% |
| 2020 | AU$71.56 Million | +86.65% |
| 2019 | AU$38.34 Million | +12.34% |
| 2018 | AU$34.13 Million | -28.51% |
| 2017 | AU$47.73 Million | -31.06% |
| 2016 | AU$69.24 Million | +86.68% |
| 2015 | AU$37.09 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 23rd, 2026 the market cap of Nova EYE Medical Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $26.20 Million USD |
| MoneyControl | $26.20 Million USD |
| MarketWatch | $26.20 Million USD |
| marketcap.company | $26.20 Million USD |
| Reuters | $26.20 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Nova EYE Medical Ltd
Nova Eye Medical Limited designs, develops, manufactures, markets, and sells surgical devices for the treatment of glaucoma in Australia, the United States, Europe, the Asia Pacific, and internationally. The company operates through Glaucoma Surgical Devices and AlphaRET segments. It offers 2RT, a proprietary laser technology to treat patients in early and intermediate age-related macular degener… Read more